Screening for barrett's esophagus and esophageal adenocarcinoma: Rationale, recent progress, challenges, and future directions

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 4, 2015, Pages 623-634

  Sami, Sarmed S ^a   Ragunath, Krish ^a   Iyer, Prasad G ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

Barrett's Esophagus; Esophageal Adenocarcinoma; Risk Stratification; Screening; Screening Tools

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CANCER SCREENING; CAPSULE ENDOSCOPE; CAPSULE ENDOSCOPY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FUTUROLOGY; HIGH RISK POPULATION; HISTOLOGY; HUMAN; IMAGING SYSTEM; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; RISK ASSESSMENT; SCREENING TEST; ADENOCARCINOMA; COMPLICATION; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; MASS SCREENING; PROCEDURES; SECONDARY PREVENTION; UTILIZATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; EARLY DIAGNOSIS; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; HUMANS; MASS SCREENING; SECONDARY PREVENTION;

EID: 84925096803     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.03.036     Document Type: Article

References (89)

1. Pohl H., Sirovich B., Welch H.G. Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev 2010, 19:1468-1470.
2. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. JNatl Cancer Inst 2005, 97:142-146.
3. Auvinen M.I., Sihvo E.I., Ruohtula T., et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. JClin Oncol 2002, 20:2971-2979.
4. Prasad G.A., Wu T.T., Wigle D.A., et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009, 137:815-823.
5. Wani S., Drahos J., Cook M.B., et al. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc 2014, 79:224-232.e1.
6. Pech O., May A., Manner H., et al. Long-term efficacy and safetyof endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014, 146:652-660.e1.
7. Dulai G.S., Guha S., Kahn K.L., et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002, 122:26-33.
8. Chak A., Faulx A., Eng C., et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 2006, 107:2160-2166.
9. Hvid-Jensen F., Pedersen L., Drewes A.M., et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEngl J Med 2011, 365:1375-1383.
10. Kadri S.R., Lao-Sirieix P., O'Donovan M., et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010, 341:c4372.
11. Peery A.F., Hoppo T., Garman K.S., et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc 2012, 75:945-953.
12. Shariff M.K., Bird-Lieberman E.L., O'Donovan M., et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. Gastrointest Endosc 2012, 75:954-961.
13. Chang J.Y., Talley N.J., Locke G.R., et al. Population screening for Barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc 2011, 86:1174-1180.
14. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014, 63:7-42.
15. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-e52.
16. Lao-Sirieix P., Fitzgerald R.C. Screening for oesophageal cancer. Nat Rev Clin Oncol 2012, 9:278-287.
17. Machii R., Saito H. Time trends in cervical cancer screening rates in the OECD countries. Jpn J Clin Oncol 2011, 41:731-732.
18. Benson V.S., Patnick J., Davies A.K., et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008, 122:1357-1367.
19. Desai T.K., Krishnan K., Samala N., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-976.
20. Corley D.A., Mehtani K., Quesenberry C., et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013, 145:312-319.
21. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011, 106:1447-1455.
22. Sikkema M., de Jonge P.J., Steyerberg E.W., et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244.
23. Cooper G.S., Yuan Z., Chak A. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 2002, 95:32-38.
24. Cooper G.S., Kou T.D., Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol 2009, 104:1356-1362.
25. Das A., Singh V., Fleischer D.E., et al. Acomparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol 2008, 103:1340-1345.
26. Bennett C., Vakil N., Bergman J., et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012, 143:336-346.
27. Inadomi J.M., Somsouk M., Madanick R.D., et al. Acost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009, 136:2101-2114.
28. Bell G.D. Review article: premedication and intravenous sedation for upper gastrointestinal endoscopy. Aliment Pharmacol Ther 1990, 4:103-122.
29. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2009. Available at: Accessed November 2, 2013. http://www.screening.nhs.uk/criteria.
30. Falk G.W., Chittajallu R., Goldblum J.R., et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997, 112:1787-1797.
31. Rader A.E., Faigel D.O., Ditomasso J., et al. Cytological screening for Barrett's esophagus using a prototype flexible mesh catheter. Dig Dis Sci 2001, 46:2681-2686.
32. Benaglia T., Sharples L.D., Fitzgerald R.C., et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013, 144:62-73.
33. Eliakim R., Sharma V.K., Yassin K., et al. Aprospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. JClin Gastroenterol 2005, 39:572-578.
34. Sharma P., Wani S., Rastogi A., et al. The diagnostic accuracy of esophageal capsule endoscopy in patients with gastroesophageal reflux disease and Barrett's esophagus: a blinded, prospective study. Am J Gastroenterol 2008, 103:525-532.
35. Bhardwaj A., Hollenbeak C.S., Pooran N., et al. Ameta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009, 104:1533-1539.
36. Rubenstein J.H., Inadomi J.M., Brill J.V., et al. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 2007, 5:312-318.
37. Ramirez F.C., Akins R., Shaukat M. Screening of Barrett's esophagus with string-capsule endoscopy: a prospective blinded study of 100 consecutive patients using histology as the criterion standard. Gastrointest Endosc 2008, 68:25-31.
38. Sami SS, Subramanian V, Ortiz-Fernández-Sordó J, et al. The utility of ultrathin endoscopy as a diagnostic tool for Barrett's oesophagus (BO). Systematic review and meta-analysis United European Gastroenterology Week. Volume UEG13-ABS-2547. Berlin,2013.
39. Alashkar B., Faulx A.L., Hepner A., et al. Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12:785-792.
40. Gora M.J., Sauk J.S., Carruth R.W., et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med 2013, 19:238-240.
41. Taylor J.B., Rubenstein J.H. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol 2010, 105:1729-1737.
42. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEngl J Med 1999, 340:825-831.
43. Gerson L.B., Shetler K., Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002, 123:461-467.
44. Ward E.M., Wolfsen H.C., Achem S.R., et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006, 101:12-17.
45. Zagari R.M., Fuccio L., Wallander M.A., et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008, 57:1354-1359.
46. Dent J., El-Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54:710-717.
47. Balasubramanian G., Singh M., Gupta N., et al. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol 2012, 107:1655-1661.
48. Eloubeidi M.A., Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. JClin Gastroenterol 2001, 33:306-309.
49. Wong A., Fitzgerald R.C. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005, 3:1-10.
50. Singh S., Sharma A.N., Murad M.H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review andmeta-analysis. Clin Gastroenterol Hepatol 2013, 11:1399-1412.
51. Juhasz A., Mittal S.K., Lee T.H., et al. Prevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma. JClin Gastroenterol 2011, 45:867-871.
52. Su Z., Gay L.J., Strange A., et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012, 44:1131-1136.
53. Orloff M., Peterson C., He X., et al. Germline mutations in msr1, ascc1, and cthrc1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011, 306:410-419.
54. Cook M.B., Shaheen N.J., Anderson L.A., et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012, 142:744-753.
55. Rubenstein J.H., Mattek N., Eisen G. Age- and sex-specific yield of Barrett's esophagus by endoscopy indication. Gastrointest Endosc 2010, 71:21-27.
56. Rubenstein J.H., Scheiman J.M., Sadeghi S., et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011, 106:254-260.
57. Thrift A.P., Kendall B.J., Pandeya N., et al. Aclinical risk prediction model for Barrett esophagus. Cancer Prev Res 2012, 5:1115-1123.
58. Rubenstein J.H., Morgenstern H., Appelman H., et al. Prediction of Barrett's esophagus among men. Am J Gastroenterol 2013, 108:353-362.
59. Thrift A.P., Garcia J.M., El-Serag H.B. Amultibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2013 Dec 19, Epub ahead of print.
60. Bhat S., Coleman H.G., Yousef F., et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. JNatl Cancer Inst 2011, 103:1049-1057.
61. de Jonge P.J., van Blankenstein M., Grady W.M., et al. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 2014, 63:191-202.
62. Coleman H.G., Bhat S., Johnston B.T., et al. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology 2012, 142:233-240.
63. Switzer-Taylor V., Schlup M., Lubcke R., et al. Barrett's esophagus: a retrospective analysis of 13 years surveillance. JGastroenterol Hepatol 2008, 23:1362-1367.
64. Moons L.M., Kusters J.G., Bultman E., et al. Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. JPathol 2005, 207:269-276.
65. Kaye P.V., Haider S.A., Ilyas M., et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009, 54:699-712.
66. Bird-Lieberman E.L., Dunn J.M., Coleman H.G., et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012, 143:927-935.
67. Kastelein F., Biermann K., Steyerberg E.W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013, 62:1676-1683.
68. Thrift A.P., Kendall B.J., Pandeya N., et al. Amodel to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013, 11:138-144.
69. Atkinson M., Das A., Faulx A., et al. Ultrathin esophagoscopy in screening for Barrett's esophagus at a Veterans Administration Hospital: easy access does not lead to referrals. Am J Gastroenterol 2008, 103:92-97.
70. Gerson L.B., Edson R., Lavori P.W., et al. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001, 96:2005-2012.
71. Avidan B., Sonnenberg A., Schnell T.G., et al. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002, 47:256-264.
72. Chak A., Lee T., Kinnard M.F., et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002, 51:323-328.
73. Smith K.J., O'Brien S.M., Smithers B.M., et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005, 14:2481-2486.
74. Cook M.B., Wild C.P., Forman D. Asystematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005, 162:1050-1061.
75. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133:34-41.
76. Johansson J., Hakansson H.O., Mellblom L., et al. Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007, 42:148-156.
77. Edelstein Z.R., Farrow D.C., Bronner M.P., et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007, 133:403-411.
78. Anderson L.A., Watson R.G., Murphy S.J., et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007, 13:1585-1594.
79. Cook M.B., Greenwood D.C., Hardie L.J., et al. Asystematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008, 103:292-300.
80. Edelstein Z.R., Bronner M.P., Rosen S.N., et al. Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol 2009, 104:834-842.
81. Kubo A., Levin T.R., Block G., et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009, 136:806-815.
82. Anderson L.A., Cantwell M.M., Watson R.G., et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009, 136:799-805.
83. Thompson O.M., Beresford S.A., Kirk E.A., et al. Vegetable and fruit intakes and risk of Barrett's esophagus in men and women. Am J Clin Nutr 2009, 89:890-896.
84. Smith K.J., O'Brien S.M., Green A.C., et al. Current and past smoking significantly increase risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2009, 7:840-848.
85. Leggett C.L., Gorospe E.C., Calvin A.D., et al. Obstructive sleep apnea is a risk factor for Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12:583-588.
86. Thrift A.P., Kramer J.R., Richardson P.A., et al. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci 2014, 59:108-116.
87. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12:229-238.
88. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
89. Hirota W.K., Zuckerman M.J., Adler D.G., et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006, 63:570-580.